In our study, the AML group showed elevated TGFβ1 mRNA levels compared to the IDA control group (p < 0.001); conversely, TGFβR2 was downregulated in AML patients (p = 0.09, Fig. 5b). This evidence concerns the gene TGFB1 and acute myeloid leukemia.